HIND (Vyome Holdings Inc.) Book Value per Share
Vyome Holdings Inc (HIND) is a pre-commercial biopharma startup whose survival depends on external financing due to a lack of revenue. However, the development of immunotherapy for autoimmune pathologies paves the way for mass production with low cost of goods sold. This chart of historical book value per share illustrates net asset dynamics, where 0.86 represents the current level of the metric. The company's strategy is based on the independent development of its dermatological pipeline and clinical trials.
Summary analytical data breakdowns for reshapelifesciences.com (HIND)
- current quotes and average value forecast:
- business market valuation indicators:
- business book valuation details:
- debt burden and liquidity indicators:
Total Debt to Capital Vyome Holdings Inc|HIND - Long-Term Debt to Capital|Short-Term Debt to Equity Vyome Holdings|HIND - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Vyome Holdings Inc.|HIND - Company Long-Term Liabilities|Company Short-Term Debts Vyome Holdings|Quick Liquidity Indicator reshapelifesciences.com
- earnings and multiples data:
General company analysis:HIND - ReShape Lifesciences
Book value per share reflects the portion of net assets attributable to a single security, allowing for an assessment of the business's intrinsic value net of all liabilities. By analyzing the book value per share of Vyome Holdings Inc (HIND), an investor can track capital dynamics, which for Vyome Holdings Inc (HIND) depends directly on the value of patents and R&D assets under strict FDA oversight.
Competitor analysis
ARGX - Net Assets per Single Share|BNTX (BioNTech Pharma) - Equity per Share|ABVX: Book Value per Share|Equity per Share ADMA|Net Assets per Single Share Protagonist|Immunovant Inc - Share Book Value|Book Value per Share KNSA|GRFS (Grifols Biemat) - Accounting Value of a Share|Book Value per Share ADPT (Adaptive Biotechnologies)|Book Value per Share celldex.com CLDX|AUPH - Net Assets per Single Share|Accounting Value of a Share BCRX (BioCryst Pharmaceuticals, Inc.)|Vera Pharma (VERA) - Net Assets per Single Share|Accounting Value per Share Dianthus Corp|PHVS (Pharvaris N.V.) - Book Value per Share|Book Value per Share AbCellera Corp|Accounting Value per Share TRML (Tourmaline Bio)|PGEN (Precigen Inc) - Accounting Value of a Share|Book Value per Share PHAR (Pharming)|Net Assets per Share Nektar Corp (NKTR)|UPB - Net Assets per Single Share|zenasbio.com (ZBIO) - Accounting Value per Share|Immunome (IMNM) - Net Assets per Single Share|Accounting Value per Share Gossamer Bio Inc|Accounting Value per Share KALV|Book Value per Share Septerna Pharma|Net Assets per Single Share Pieris Pharmaceuticals (PVLA)|savarapharma.com - Equity per Share|Book Value per Share RIGL (Rigel Pharmaceuticals, Inc.)|AnaptysBio Inc (ANAB) - Net Asset Value per Share|ATXS: Accounting Value per Share|ENGN: Net Assets per Single Share|RAPT (RAPT Therapeutics, Inc.) - Accounting Value per Share|Net Asset Value per Share Aerovate Therapeutics (JBIO)|Net Assets per Single Share Aclaris Therapeutics, Inc.|Net Asset Value per Share Kyverna Therapeutics Inc. KYTX|Net Assets per Single Share Tiziana Life Sciences PLC (TLSA)|Accounting Value per Share Cabaletta Bio Inc CABA|Book Value per Share VTYX (Ventyx Biosciences)|theratech.com (THTX) - Net Asset Value per Share|AVTX: Accounting Value per Share|Accounting Value of a Share ELDN (Eledon Pharmaceuticals Inc.)|AGEN: Book Value per Share|Climb Bio, Inc - Accounting Value of a Share|Net Assets per Single Share Zura Bio Limited|Net Asset Value per Share atyrpharma.com ATYR|Net Assets per Single Share Adagene (ADAG)|Net Assets per Single Share IMA (ikenaoncology.com)|Book Value per Share STTK (Shattuck Labs)|EQ: Equity per Share|Connect Pharma - Book Value per Share|Net Assets per Share Immunic, Inc. IMUX|atarabio.com (ATRA) - Net Assets per Single Share|Equity per Share IFRX|XFOR (X4 Pharma) - Book Value per Share|ACET - Book Value of One Share|Net Assets per Single Share Celularity Inc. (CELU)|Net Assets per Share inmunebio.com|Barinthus Biotherapeutics plc - Accounting Value per Share|Accounting Value of a Share KZR|SAB Biotherapeutics, Inc - Book Value per Share|Net Assets per Share Akari Therapeutics, Plc AKTX|enlivex.com (ENLV) - Net Assets per Single Share|Equity per Share QTTB|GOVX (GeoVax) - Book Value per Share|Accounting Value per Share Edesa Biotech Inc (EDSA)|Book Value per Share IBIO|CARM (carismatx.com) - Accounting Value of a Share|Book Value per Share XTLB (XTL Biopharmaceuticals)|Net Assets per Share Bolt Biotherapeutics Inc. (BOLT)|HCWB - Net Assets per Single Share|APVO (Aptevo Therapeutics) - Equity per Share|AIM: Book Value per Share|Equity per Share ADTX|Net Assets per Single Share GRI Bio, Inc.|xortx.com - Share Book Value|Book Value per Share REVB|INDP (Indaptus Therapeutics Inc) - Accounting Value of a Share|Book Value per Share SCNI (Scinai)|Book Value per Share CalciMedica Inc CALI|AFMD - Net Assets per Single Share|Accounting Value of a Share ALLK (Allakos Inc.)|hookipapharma.com (HOOK) - Net Assets per Single Share|Accounting Value per Share IGM Biosciences|ITOS (iTeos) - Book Value per Share|Book Value per Share Ocean Biomedical Corp|Accounting Value per Share TCBP (TC Biopharm)|THRD (thirdharmonicbio.com) - Accounting Value of a Share